Pfizer and Sangamo’s haemophilia gene therapy shows increased factor VIII levels

pharmafile | December 9, 2019 | News story | Manufacturing and Production, Sales and Marketing American Society of Hematology, Pfizer, Sangamo Therapeutics, hematology 

Pfizer and Sangamo Therapeutics have revealed that their investigational gene therapy, SB-525, sustained increased factor VIII (FVIII) levels in patients with haemophilia A through to 44 weeks following treatment.

The trial data from April showed that two patients administered with the highest dose of SB-525 had reached normal FVIII levels. More results in July from 10 subjects demonstrated a dose-dependent increase in FVIII activity levels.

At the American Society of Hematology (ASH) the updated results from the Phase 1/2 Alta study were presented. The findings were from 11 patients treated across four ascending dose cohorts, with five subjects receiving the highest does of 3e13 vg/kg. The results show that patients receiving this dose achieved normal range FVIII activity within five to seven weeks of treatment with SB-525.

Barbara Konkle, Professor of Medicine at University of Washington and a Principal Investigator of the Alta study, said: “It is important to continue to follow these patients to determine whether these results are sustained in the longer term as the combination of a favourable safety profile coupled with sustained expression at a level that prevents bleeding and allows normal activity will be the hallmark of a successful gene therapy for haemophilia A.”

Application to Pfizer is expected to be completed in the first quarter of 2020, and Sangamo has completed the manufacturing technology transfer and initiated the transfer of the Investigational New Drug. Pfizer is enrolling patients in the Phase 3 lead-in study. This data will provide a baseline for patients who will be enrolled into the Phase 3 trial.

Conor Kavanagh

Related Content

EC approves Pfizer’s Emblaveo for multidrug-resistant infection treatment

Pfizer has announced that the European Commission (EC) has granted marketing authorisation for Emblaveo (aztreonam-avibactam) …

Pfizer’s Velsipity approved by EC for ulcerative colitis treatment

Pfizer has announced that the European Commission (EC) has granted marketing authorisation for Velsipity (etrasimod) …

EC approves Pfizer’s Elrexfio for relapsed and refractory multiple myeloma

Pfizer has announced that the European Commission (EC) has granted conditional marketing authorisation for Elrexfio …

Latest content